CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Wash Sale Rules Crypto Gains 2026
This article clarifies which crypto transactions trigger wash sale rules in 2026 and how they alter reported gains and tax liability.
25,192 articlesStock Market Crash 2026? What Investors Should Do Right Now
Is a stock market crash 2026? on the horizon. This guide translates fear into a concrete action plan—emergency funds,...
Power Solutions International Drawing Investor Attention in 2026
Power Solutions International posted a softer-than-expected Q1 2026, with revenue miss and shrinking margins. Data-ce...
Barclays Thinks Ionis Headed Toward a $106 Target This Year
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
Here's Metals Company Stock: Why It Dropped in 2026
The Metals Company stock faced a sharp pullback in early 2026 after a dramatic rally in the previous year. This artic...
Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Here's Shares Agios Pharmaceuticals: 2026 Outlook and Rally
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
18-Year Real Estate Cycle: What Comes Next in 2026
As 2026 approaches, the idea of an 18-year real estate cycle sparks questions for borrowers and investors. This guide...
Prediction: DraftKings Could Surprise If Markets Deliver
DraftKings reports a mixed Q1 2026 while signaling growth hinges on prediction markets and regulatory clarity. A path...
March 18 Date Social: Fed Meeting Could Shape COLA Outlook
A key Fed decision on March 18 could set the tone for inflation and, in turn, the Social Security COLA for 2027. Reti...
Dave Ramsey’s Million Promise Faces Scrutiny in 2026
A 23-year-old Chicago homeowner wipes out $25,000 in debt and now weighs emergency fund needs against a 15% savings p...
Molson Coors Could Drop 3% as Barclays Cuts Target to $40
Barclays slashed Molson Coors' price target to $40, underscoring earnings headwinds as the brewer anticipates a tough...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status